Cardio-Metabolic Summit

Cardio-Metabolic Summit Agenda
Saturday, April 27, 2013
Four Seasons Hotel ~ Toronto, ON
Co-Chairs: Lawrence Leiter, MD | Peter Lin, MD

This event is an accredited group learning activity under Section 1 as defined by the Royal College of Physicians & Surgeons of Canada for the Maintenance of Certification program. Approved by the Canadian Cardiovascular Society for a maximum of 8 credits.

This program was co-developed with the Canadian Cardiovascular Society and the Canadian Heart Research Centre and was planned to ensure the evidence presented is valid, objective and balanced.

7:30	Registration and Breakfast
8:15	Introduction and Welcome	Lawrence Leiter, MD
8:20	ARS Questions	Peter Lin, MD
8:25	Case of Mr. L	Peter Lin, MD
8:30	2013 CDA Guidelines: A1C for diagnosis and targets	Ronald Goldenberg, MD
8:45	2013 CDA Guidelines: What could come after metformin and why	Amir Hanna, MD
9:00	Why Should We Care About Hypoglycemia and Who is at Risk?	Peter Lin, MD
9:15	Practical Tips on Starting and Titrating Insulin	Amir Hanna, MD
9:30	Exercise and its Benefits for Diabetes and Cardiovascular Disease	Paul Oh, MD
9:45	Interactive Panel Discussion and Q & A with ARS	Faculty
10:20	Health Break
10:35	ARS Questions	Peter Lin, MD
10:40	Case: Mr. L – What is his CV risk?	Peter Lin, MD
10:45	2013 CDA Guidelines: Pregnancy and Diabetes	Tina Kader, MD
11:00	2013 CDA Guidelines: What is Mr. L's cardiovascular risk? Is it the same for everyone with diabetes?	Ronald Goldenberg, MD
11:15	2013 CDA Guidelines: How to reduce Mr. L's risk with vascular protective strategies?	Lawrence Leiter, MD
11:30	2013 CDA Guidelines: Protecting Mr. L's eyes and kidneys	Tina Kader, MD
11:45	Novel Therapies for Diabetes on the Horizon	Lawrence Leiter, MD
12:00	Interactive Panel Discussion and Q & A with ARS	Faculty
12:30 pm	Lunch
1:10	ARS Questions	Peter Lin, MD
1:15	Case: Mr. L Develops Atrial Fibrillation	Peter Lin, MD
1:20	Why is Stroke Prevention so Important in Atrial Fibrillation?	Leanne Casaubon, MD
1:35	Why is Warfarin so Hard to Use?	Peter Lin, MD
1:50	What do the Studies say about the New Oral Anticoagulants?	Iqwal Mangat, MD
2:05	Pearls on using these New Oral Anticoagulants – Switching, starting, stopping	Yaariv Khaykin, MD
2:20	ACS: New antiplatelet therapies – What do we need to know?	John Graham, MD
2:35	Interactive Panel Discussion and Q & A and ARS	Faculty
3:10	Health Break
3:20	ARS Questions	Peter Lin, MD
3:25	CCS Dyslipidemia Guidelines: LDL-C and how low should we go and what is non HDL?	Paul Oh, MD
3:40	2013 CHEP guidelines: What’s new and what’s still important?	Jordan Weinstein, MD
3:55	Sleep Apnea – Is it really that bad for you?	Peter Lin, MD
4:10	Interactive Panel Discussion and Q &A and ARS	Faculty
4:40	Evaluation and Adjournment

Cardio-Metabolic Summit 2013
Program Learning Objectives
By participating in this program, participants will be able to:

Explain the interrelationships among the various cardiometabolic risk factors, their impact on cardiovascular health, and their common comorbidities.
Translate evidence-based strategies for prevention, screening, and treatment of cardiometabolic risk factors and their comorbidities to their clinical practice.
Identify which interventions, including lifestyle changes and various therapies alone and in combination, are most appropriate for particular patients based on their risk profiles.
Identify how novel and emerging therapies can be integrated into clinical practice to reduce morbidity and mortality from cardiovascular and metabolic disease.
Implement strategies for effectively managing high-risk patients according to guidelines.